Cytheris SA Receives €1.5 Million ($2.3 Million) from OSEO for HCV Clinical Development Program  
7/15/2008 9:52:21 AM

PARIS--(BUSINESS WIRE)--Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that OSEO, France's national agency for industrial innovation, has awarded the company with a no interest loan of €1.5 million, or $2.3 million, to support its ongoing clinical development program in hepatitis C (HCV).